The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preoperative chemoradiation (CRT) with concurrent capecitabine (Cap), oxaliplatin (Ox), and bevacizumab (Bev) in patients with locally advanced rectal cancer (RC): Effects on pathological complete response (pCR) and surgical complications.
T. Hoehler
No relevant relationships to disclose
K. Dellas
Honoraria - Roche
D. Riesenbeck
No relevant relationships to disclose
T. Reese
No relevant relationships to disclose
F. Wuerschmidt
No relevant relationships to disclose
C. Roedel
Honoraria - Merck Serono; Roche; Sanofi
Research Funding - Merck Serono; Roche; Sanofi
W. Wagner
No relevant relationships to disclose
H. Zuehlke
Honoraria - Merck; Roche
M. Richter
No relevant relationships to disclose
J. Dunst
Honoraria - Roche
Research Funding - Roche